|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
|
|
SIDE EFFECTS:
|
|
cyanosis |
|
diaphoresis |
|
dizziness |
|
flushing |
|
headache |
|
hypotension |
|
methemoglobinemia |
|
nausea/vomiting |
|
orthostatic hypotension |
|
sinus tachycardia |
|
syncope |
|
tolerance |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
abrupt discontinuation |
|
anemia |
|
breast-feeding |
|
cardiomyopathy |
|
children |
|
dehydration |
|
elderly |
|
GI disease |
|
glaucoma |
|
hyperthyroidism |
|
hypotension |
|
hypovolemia |
|
myocardial infarction |
|
orthostatic hypotension |
|
pregnancy |
|
|
ADULT DOSE:
|
|
Antianginal-
Oral, 20 mg two times a day, with the two doses given seven hours apart.
Note: An initial dose of 5 mg may be appropriate for patients of particularly small stature; the dosage being increased to at least 10 mg by the second or third day of therapy. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|